Pharma Equity Group (PEG) Investor Update summary

Investment Model and Strategy

• Focuses on repurposing known APIs for new indications to reduce risk and cost.

• Identifies promising compounds, validates them in small clinical trials, and develops proprietary formulations.

• Seeks co-development partners and aims for exit via out-licensing or sale at Phase 2 proof-of-concept.

• All resources are currently dedicated to advancing projects, with new investments considered only after current projects reach full potential.

Target Indications and Unmet Needs

• Targets colorectal cancer prevention and secondary bacterial peritonitis, both lacking approved preventative or adjuvant therapies.

• Addresses significant clinical voids where standard of care relies on screening or lacks mid-surgery interventions.

• Focus on innovative therapies to improve healthcare outcomes.

Clinical Trial Updates and Outcomes

• RNX-011 triple therapy trial for secondary peritonitis shows 85% reduction in hospital stay and 55% better patient-reported recovery.

• Phase 2 IIT confirmatory trial for RNX-011 is designed with primary endpoints of reduced local inflammation and improved recovery quality.

• RNX-051 ENABLE trial protocol is in design phase, targeting high-risk adenoma patients with international partners.

• Received approval to initiate a pivotal Phase 2 clinical trial for RNX-011 targeting secondary peritonitis.

• The RNX-011 trial is randomized, placebo-controlled, and will test a triple-action therapy administered during surgery, with primary endpoint of reducing serious postoperative complications.